Tag: chemotherapy drug

• 97% of HER2+, early-stage patients treated with trastuzumab emtansine (T-DM1) were free of cancer recurrence five years after treatment

• Prognostic test (HER2DX) shown helpful in identifying patients at greatest risk for recurrence